Personalized Medicine Personalized Medicine – Drug Development Forum Highlights Trends
Personalised drugs and medicine could revolutionise the treatment of cancer patients – but they still have a long way to go. The Fifth Drug Development Forum in Wuerzburg served as a melting pot for researchers and industries.
Most Western societies, but also the population of several Asian states like Japan, are ageing. In the wake of this welcome development, age related illnesses move into the focus of attention.. Now genetic analysis offer a deeper understanding of cardiac insufficiencies and cancer – as a result, personalized drugs and treatments are likely to revolutionize the pharmaceutical industry.
“Goals like these can not be achieved alone,” emphasized Prof. Dr. Josef Nassauer, CEO of the German technology organisation ‘Bayern Innovativ’. To unleash the true potentials that genetic researches could bring for the pharmaceutical industry, a close cooperation of institutes, industries and clinics would be necessary, Nassauer believes.
160 Professionals Discuss Personalized Medicine
To bridge the gap between research institutes and pharmaceutical manufacturers, Bayern Innovativ held the ‘Fifth Drug Development Forum’ on December 1st at the Bavarian university town of Würzburg. About 160 professionals discussed topics from personalised medicine via antibody researches to the development of new biotechnological remedies.
Diversity Poses A Chalenge
Sequencing the genetic material of tumour cells led to a surprise: “We used to believe that a tumour consists of tumour cells and tumour cells only,” said Prof. Peter Lichter of the German Cancer Research Centre. “Now we know that that is not the case.“ The diversity of cancer cells poses a significant challenge for physicians and researchers, he continued. His solution: Understanding the molecular expression of the DNA.
Personalized Solutions for Pharmaceuticals
The exact classification of tumour cells could reveal weaknesses and possible targets. But the “unexpected diversity of tumour cells“ calls for individual treatments. “Of course a certain remedy can no longer be applied to all patients. The more we know, the less patients will be treated the same,” Lichter added.
Bio-Informatics Have a Key Role
But these are still dreams of the future. Recently it’s the bio-informatics that slow down the individual sequencing of chromosome sets, the speakers explained. The expenses for the storage and evaluation of a sequenced genome are more than ten times those of the sequencing itself, Lichter explained.